research presentation icon

• Notifications

No notifications to show yet

You’ll see useful information here soon. Stay tuned!

• Animated icons
• Interface icons

Are you sure you want to delete this collection?

We’re sorry you canceled your Premium subscription

You can still enjoy Flaticon Collections with the following limits:

• You can choose only 3 collections to keep
• You can only add up to 100 icons per collection
• You can’t add Premium icons to your collection

The advantages of your collections have changed

Keep making the most of your icons and collections

20% OFF our Annual Premium Plan

Select 3 collections to continue:

You have 8 collections, but can only unlock 3 of them

Report download

Please indicate what problem has been found. Thanks!

Base 64 encoded image

Copy the base64 encoded data and insert it in your HTML or CSS document. Need help? Maybe this link can help you

CSS background

Using it for the web? Copy this link in your website:

How to attribute for other media?

Don’t you want to attribute the author?

Going Premium is easy and it also allows you to use more than 15,492,500 icons without attribution. Find out more information here

Select a color from the icon

Choose a new color

Custom palette

• Remove color
• Remove palette
• You have exceeded the number of color samples for this palette

Select a shape

Stroke width

You can only save 3 new edited icons per collection as a free user. Upgrade to save unlimited icons.

Your collection is locked. You can upgrade your account to get an unlimited collection.

You have reached the icons limit per collection (256 icons)

This feature is only available for registered users. Login or register

This icon has a gradient color and cannot be edited.

Group search results

You can group your results by author style, pack, or see all available icons on your screen.

Research Icons

• Delete filters

• Add to collection
• Copy to clipboard. Copying this asset counts as a download Copy to clipboard SVG PNG

Set your own limits

Gain access to over 15,492,500 icons in formats SVG, EPS, PSD & BASE64

Download what you want, cancel when you want

Related tags

Collection:

Over 15,492,500 icons for 8.25 USD /month

• No attribution required
• 15.5M icons & stickers in SVG, EPS, PSD & BASE64
• Unlimited downloads
• Browse ad-free

You must attribute the author

How to attribute for other media? How to attribute?

How likely are you to recommend Flaticon to a friend?

How about giving us a rating on Trustpilot

If you can spare a few minutes to leave us a review, we’d be super grateful 😃

Please visit:

• Research and development
• Development

Research icons

• Apps & Plugins

Noun Project

• Submit Icons
• Submit Photos
• Customer Support
• Affiliate Program

Browse Research Presentation Icons

80 Research Icon Set

Get 30K icons: 2D, 3D, animated. Lifetime deal at $149

80 Research Vector Icons

Looking to enhance your academic website or make your scientific presentations more engaging? Wish to provide intuitive navigation for your research database or visual aids for your educational materials? We’ve got just the thing!

Introducing the 80 Research Icon Set. From microscopes and test tubes to data charts and books, this unique icon pack grabs everyone’s attention.

Best of all? You can customize the icons yourself. Change their size, shape, or color and make them perfect for your project. Enjoy!

Visualize scientific breakthroughs featuring our biotechnology icons and physics icons . Customize for an immersive experience on groundbreaking discoveries!

TL;DR: 80 research vector icons. 5 formats, fully customizable. Find the full icon list below.

Why get this icon set:

• 100% customizable
• Niche-specific
• Five file types + IconJar
• Single zip file
• Great customer support

Related Packs

Download from thousands of popular Icons by our designers

65 Video Production Icon Set

70 Weather Icon Set

60 3D Web Icons

90 Business Training Icon Set

35 Flat & Modern Avatars

60 Gamification Icons

36 Samurai Characters

20 Free Square Icons

Want lifetime access to 27,900+ premium icons with free updates.

Special price $4172 $149

Your Cart 0

Nothing Found

Make scientific figures in minutes

Create publication-quality figures with pre-made icons and templates, all from biorender's web-based software.

Make scientific figures for your lectures, publications, meetings, posters, and more

Looking for science content?

Browse 50K+ icons and templates that are peer-reviewed, easy to use, and free.

• Images home
• Editorial home
• Editorial video
• Premium collections
• Entertainment
• Premium images
• AI generated images
• Curated collections
• Animals/Wildlife
• Backgrounds/Textures
• Beauty/Fashion
• Buildings/Landmarks
• Business/Finance
• Celebrities
• Food and Drink
• Healthcare/Medical
• Illustrations/Clip-Art
• Miscellaneous
• Parks/Outdoor
• Signs/Symbols
• Sports/Recreation
• Transportation
• All categories
• Shutterstock Select
• Shutterstock Elements
• Health Care
• Sound effects

PremiumBeat

• PixelSquid 3D objects
• Templates Home
• Instagram all
• Highlight covers
• Facebook all
• Carousel ads
• Cover photos
• Event covers
• Youtube all
• Channel Art
• Etsy big banner
• Etsy mini banner
• Etsy shop icon
• Pinterest all
• Pinterest pins
• Twitter All
• Twitter Banner
• Infographics
• Zoom backgrounds
• Announcements
• Certificates
• Gift Certificates
• Real Estate Flyer
• Travel Brochures
• Anniversary
• Baby Shower
• Mother's Day
• Thanksgiving
• All Invitations
• Party invitations
• Wedding invitations
• Book Covers
• About Creative Flow
• Start a design

AI image generator

• Photo editor
• Background remover
• Collage maker
• Resize image
• Color palettes

Color palette generator

• Image converter
• Creative AI
• Design tips
• Custom plans
• Request quote
• Shutterstock Studios
• Data licensing

You currently have 0 credits

See all plans

Image plans

With access to 400M+ photos, vectors, illustrations, and more. Includes AI generated images!

Video plans

A library of 28 million high quality video clips. Choose between packs and subscription.

Music plans

Download tracks one at a time, or get a subscription with unlimited downloads.

Editorial plans

Instant access to over 50 million images and videos for news, sports, and entertainment.

Includes templates, design tools, AI-powered recommendations, and much more.

Ppt Research Icon royalty-free images

152 ppt research icon stock photos, vectors, and illustrations are available royalty-free for download..

Our company

Press/Media

Investor relations

Shutterstock Blog

Popular searches

Stock Photos and Videos

Stock photos

Stock videos

Stock vectors

Editorial images

Featured photo collections

Sell your content

Affiliate/Reseller

International reseller

Live assignments

Rights and clearance

Website Terms of Use

Terms of Service

Privacy policy

Modern Slavery Statement

Cookie Preferences

Shutterstock.AI

AI style types

Shutterstock mobile app

Android app

© 2003-2024 Shutterstock, Inc.

Princeton Correspondents on Undergraduate Research

How to Make a Successful Research Presentation

Turning a research paper into a visual presentation is difficult; there are pitfalls, and navigating the path to a brief, informative presentation takes time and practice. As a TA for  GEO/WRI 201: Methods in Data Analysis & Scientific Writing this past fall, I saw how this process works from an instructor’s standpoint. I’ve presented my own research before, but helping others present theirs taught me a bit more about the process. Here are some tips I learned that may help you with your next research presentation:

More is more

In general, your presentation will always benefit from more practice, more feedback, and more revision. By practicing in front of friends, you can get comfortable with presenting your work while receiving feedback. It is hard to know how to revise your presentation if you never practice. If you are presenting to a general audience, getting feedback from someone outside of your discipline is crucial. Terms and ideas that seem intuitive to you may be completely foreign to someone else, and your well-crafted presentation could fall flat.

Less is more

Limit the scope of your presentation, the number of slides, and the text on each slide. In my experience, text works well for organizing slides, orienting the audience to key terms, and annotating important figures–not for explaining complex ideas. Having fewer slides is usually better as well. In general, about one slide per minute of presentation is an appropriate budget. Too many slides is usually a sign that your topic is too broad.

Limit the scope of your presentation

Don’t present your paper. Presentations are usually around 10 min long. You will not have time to explain all of the research you did in a semester (or a year!) in such a short span of time. Instead, focus on the highlight(s). Identify a single compelling research question which your work addressed, and craft a succinct but complete narrative around it.

You will not have time to explain all of the research you did. Instead, focus on the highlights. Identify a single compelling research question which your work addressed, and craft a succinct but complete narrative around it.

Craft a compelling research narrative

After identifying the focused research question, walk your audience through your research as if it were a story. Presentations with strong narrative arcs are clear, captivating, and compelling.

• Introduction (exposition — rising action)

Orient the audience and draw them in by demonstrating the relevance and importance of your research story with strong global motive. Provide them with the necessary vocabulary and background knowledge to understand the plot of your story. Introduce the key studies (characters) relevant in your story and build tension and conflict with scholarly and data motive. By the end of your introduction, your audience should clearly understand your research question and be dying to know how you resolve the tension built through motive.

• Methods (rising action)

The methods section should transition smoothly and logically from the introduction. Beware of presenting your methods in a boring, arc-killing, ‘this is what I did.’ Focus on the details that set your story apart from the stories other people have already told. Keep the audience interested by clearly motivating your decisions based on your original research question or the tension built in your introduction.

• Results (climax)

Less is usually more here. Only present results which are clearly related to the focused research question you are presenting. Make sure you explain the results clearly so that your audience understands what your research found. This is the peak of tension in your narrative arc, so don’t undercut it by quickly clicking through to your discussion.

• Discussion (falling action)

By now your audience should be dying for a satisfying resolution. Here is where you contextualize your results and begin resolving the tension between past research. Be thorough. If you have too many conflicts left unresolved, or you don’t have enough time to present all of the resolutions, you probably need to further narrow the scope of your presentation.

• Conclusion (denouement)

Return back to your initial research question and motive, resolving any final conflicts and tying up loose ends. Leave the audience with a clear resolution of your focus research question, and use unresolved tension to set up potential sequels (i.e. further research).

Use your medium to enhance the narrative

Visual presentations should be dominated by clear, intentional graphics. Subtle animation in key moments (usually during the results or discussion) can add drama to the narrative arc and make conflict resolutions more satisfying. You are narrating a story written in images, videos, cartoons, and graphs. While your paper is mostly text, with graphics to highlight crucial points, your slides should be the opposite. Adapting to the new medium may require you to create or acquire far more graphics than you included in your paper, but it is necessary to create an engaging presentation.

The most important thing you can do for your presentation is to practice and revise. Bother your friends, your roommates, TAs–anybody who will sit down and listen to your work. Beyond that, think about presentations you have found compelling and try to incorporate some of those elements into your own. Remember you want your work to be comprehensible; you aren’t creating experts in 10 minutes. Above all, try to stay passionate about what you did and why. You put the time in, so show your audience that it’s worth it.

For more insight into research presentations, check out these past PCUR posts written by Emma and Ellie .

— Alec Getraer, Natural Sciences Correspondent

Share this:

• Share on Tumblr

• Vector Collections

Research Vectors

Free Research SVG Vectors and Icons. Research icons and vector packs for Sketch, Figma, websites or apps. Browse 50 vector icons about Research term.

No Ads here 🤗

Instead, you can give us a Share on Twitter.

Related Collections

Website content.

Search, explore, edit and share open-licensed SVG vectors

Free Vectors

• Monocolor Vectors
• Multicolor Vectors
• Filled Vectors
• Outlined Vectors
• Icon Vectors

Other Collections

• Glyphs Vectors
• Circular Vectors
• Duotone Vectors
• Flat Vectors
• Submit Assets

Developers / Designers

• vectormaker

• Customer Favourites

Research Icon

Powerpoint Templates

Icon Bundle

Kpi Dashboard

Professional

Business Plans

Swot Analysis

Gantt Chart

Business Proposal

Marketing Plan

Project Management

Business Case

Business Model

Cyber Security

Business PPT

Digital Marketing

Digital Transformation

Human Resources

Product Management

Artificial Intelligence

Company Profile

Acknowledgement PPT

PPT Presentation

Reports Brochures

One Page Pitch

Interview PPT

All Categories

• You're currently reading page 1

Stages // require(['jquery'], function ($) { $(document).ready(function () { //removes paginator if items are less than selected items per page var paginator = $("#limiter :selected").text(); var itemsPerPage = parseInt(paginator); var itemsCount = $(".products.list.items.product-items.sli_container").children().length; if (itemsCount ? ’Stages’ here means the number of divisions or graphic elements in the slide. For example, if you want a 4 piece puzzle slide, you can search for the word ‘puzzles’ and then select 4 ‘Stages’ here. We have categorized all our content according to the number of ‘Stages’ to make it easier for you to refine the results.

Category // require(['jquery'], function ($) { $(document).ready(function () { //removes paginator if items are less than selected items per page var paginator = $("#limiter :selected").text(); var itemsperpage = parseint(paginator); var itemscount = $(".products.list.items.product-items.sli_container").children().length; if (itemscount.

• Block Chain (28)
• Branding (37)
• Business Plans (79)
• Business Slides (25059)

School of Medicine Department of Family Medicine

Department of family medicine, family medicine grand rounds: exercise is medicine: for health care practitioners and patients, by rachel bengtzen, m.d., grand rounds details:.

Please join us for a virtual Grand Rounds presentation, “Exercise is Medicine: For Health Care Practitioners and Patients”, presented by Rachel Bengtzen, M.D.

What if exercise was practiced as an indispensable part of our day, rather than expendable? In this talk, we explore this paradigm shift, and I include myself as a case study. We will go through the literature on how most physicians are not meeting the minimum exercise guidelines, but that those who do, are more effectively discussing physical activity in the care of their patients. We will discuss the evidence on exercise being prescribed to prevent and even treat many common health problems. We will conclude with how to implement this in our clinical practice with how to assess and prescribe exercise as medicine to patients.

Learning Objectives:

At the end of this session, attendees should be able to:

• Describe the evidence basis of Exercise as a Medicine.
• Assess our own habits as health care practitioners in meeting minimum exercise requirements.
• Learn how to assess and prescribe exercise with patient care.

-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-~-

When it's time, join your Webex meeting here. Join Meeting: https://ohsu.webex.com/ohsu/j.php?MTID=mc4b08e28fd9610be3891d56fd81e1c56 Meeting password: QNdhzg23PK2

Phone (audio only): 1-503-388-9555 Portland, OR 1-206-207-1700 Seattle, WA Meeting number (access code): 2634 868 7899 Additional call-in numbers: https://ohsu.webex.com/ohsu/globalcallin.php

Mobile phone (one-touch): 206-207-1700 ,,26348687899##

Join from a Conference room device (press # to bypass host code) Dial [email protected] You can also dial 173.243.2.68 and enter the meeting number (26348687899)

Need help? Go to: https://www.ohsu.edu/information-technology/join-webex-online-meeting

• Skip to main content

We use cookies

Necessary cookies.

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.

Analytics cookies

Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.

Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.

Privacy policy

• Research units A-Z
• Centre for Computing Science Education
• Publications
• Community of Practice and Public Engagement

MSci Presentations: Zoltan Sojtory and Manuel Simonetta

Published: 25 April 2024

Two EAP MSci students present their research projects on large language models to support student learning and qualitative research.

SPEAKER: Zoltan Sojtory TITLE: Large Language Model-Aided Pair Programming for Algorithm Tracing DESCRIPTION: The widespread popularity of generative AI models has inspired the development of numerous large- language-model (LLM) based tools for educational purposes. We explore LLM-aided pair programming specifically for algorithm tracing, in an attempt to combine the benefits of these two traditional educational techniques. Our main objective is to address challenges inherent to pair programming while utilising the flexibility of LLM tools.

SPEAKER: Manuel Simonetta TITLE: Exploring the Use of Large Language Models in Thematic Analysis DESCRIPTION: This research investigates the use of Large Language Models (LLMs) such as OpenAI's ChatGPT and Google Bard, into thematic analysis (TA), a qualitative data analysis method. By utilising advanced prompt engineering techniques and iterative refinements, we explore how different prompting strategies influence the quality and depth of TA insights produced by LLMs. The research method is experimental, using an iterative prompt development approach and sample data. Output quality is assessed in three ways, by triangulation, using quality criteria and comparing LLM outputs to human-conducted thematic analysis. We contribute an experimental framework for LLM-conducted thematic analysis and envision that LLMs can be effectively used as co-analysts alongside humans. The paper contributes to addressing tensions surrounding technology integration in social science research and paves the way for further exploration of ethical and effective use of LLMs in research.

First published: 25 April 2024

<< Activities

<< previous story

in this issue

next story >>

Speakers: Zoltan Sojtory & Manuel Simonetta

• Phathom Pharmaceuticals-stock
• News for Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

• First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD) 1
• New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high health care resource utilization, real world treatment patterns in newly diagnosed patients and diagnostic accuracy of grading disease severity, to be presented 2,3, 4

FLORHAM PARK, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple studies for its first-in-class treatment VOQUEZNA ® (vonoprazan) including an oral presentation at Digestive Disease Week ® (DDW) 2024, being held May 18-21 in Washington, D.C.

Phathom’s Phase 3 results evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease (NERD) will be featured in an oral presentation during the congress. 1 In addition, poster presentations showcasing real-world evidence on suboptimal treatment patterns of newly diagnosed Erosive GERD patients treated with proton pump inhibitors (PPIs), and an analysis highlighting high healthcare resource utilization (HCRU) costs associated with Erosive GERD, among other important clinical data updates and broader clinical sessions, will be showcased. 2,3,4

“This year’s abstracts showcase the breadth of the data we will be presenting at DDW, reaffirming Phathom’s continued commitment to helping improve the lives of people affected by acid-related gastrointestinal disorders,” said Eckhard Leifke, M.D., Chief Medical Officer at Phathom. “Notably, we are excited to unveil novel findings highlighted in three posters and an oral presentation during the conference, including the first time data from our Phase 3 study of the investigational use of VOQUEZNA in Non-Erosive GERD will be presented during a medical congress. Our team eagerly anticipates meaningful interactions with physicians that treat the conditions we are working to transform.”

Phathom announced in December 2023 that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for VOQUEZNA as a daily treatment of heartburn associated with Non-Erosive GERD and assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

In addition to these three poster sessions and one oral presentation, Phathom will sponsor a product theater highlighting VOQUEZNA as an approved treatment for Erosive Esophagitis, also referred to as Erosive GERD, and will also have a presence on the exhibit floor at booth #911 throughout the conference.

A high-level schedule of Phathom activities at DDW 2024 can be found below:

Sunday, May 19, 2024

• Time: 6:00-8:00 pm ET
• Presenters: Prakash Gyawali, M.D.; Rena Yadlapati, M.D.; Leila Kia, M.D.
• Independent CME sponsored by Phathom Pharmaceuticals

Monday, May 20, 2024

• Time: 12:30 pm ET
• Presentation #: 4034836
• Poster Session
• Presentation #: 4036034
• Time: 12:50 pm ET
• Product theater #2
• Oral Presentation by Dr. Brooks D. Cash, M.D., Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Science Center at Houston
• Time: 4:45 pm ET
• Presentation #: 4025446
• Oral Presentation

Tuesday, May 21, 2024

• Time: 2:30 pm ET
• Presentation #: 4036411

Following the meeting, abstracts will be available on the Phathom’s publications and scientific section of the company website.

VOQUEZNA is marketed exclusively by Phathom Pharmaceuticals, Inc. Please visit VoqueznaPro.com to learn more about VOQUEZNA.

About DDW Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2024 in Washington, D.C. The meeting showcases more than 3,500 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is VOQUEZNA?

• for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
• for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.

WARNINGS AND PRECAUTIONS Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.

Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.

Clostridioides difficile -Associated Diarrhea: Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridioides difficile -associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

Bone Fracture: Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.

Severe Cutaneous Adverse Reactions (SCAR): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.

Vitamin B12 (Cobalamin) Deficiency: Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.

Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.

Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.

Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.

Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.

Fundic Gland Polyps: Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

ADVERSE REACTIONS: Healing of Erosive GERD : The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).

Maintenance of Healed Erosive GERD : The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).

DRUG INTERACTIONS VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.

USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended during treatment. Because of the potential risk of adverse liver effects shown in animal studies with vonoprazan, advise patients not to breastfeed during treatment with VOQUEZNA.

Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min).

Hepatic Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C).

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Please see full Prescribing Information for VOQUEZNA.

About Erosive GERD ( gastroesophageal reflux disease) Erosive GERD, also referred to as Erosive Esophagitis (EE), is a subtype of gastroesophageal reflux disease (GERD) characterized by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. 5 There are estimated to be over 65 million individuals with GERD in the U.S., of which approximately 30% have Erosive GERD. 6,7,8 In addition to experiencing troubling heartburn symptoms, patients with inadequately treated Erosive GERD may progress to more severe diseases including Barrett’s esophagus and esophageal cancer. 6  

About VOQUEZNA ® VOQUEZNA® (vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and numerous other countries in Asia and Latin America. 

About Phathom Pharmaceuticals, Inc.   Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward Looking Statement This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the PDUFA action date for and FDA approval of the Company’s NDA for NERD and vonoprazan’s ability to treat patients affected by acid-related gastrointestinal disorders. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom’s business, including, without limitation: we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; risks inherent in the clinical development of vonoprazan; Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom’s ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT Nick Benedetto 1-877-742-8466 [email protected]

INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 [email protected]

References:

• Loren Laine, MD, et. al.; Vonoprazan for The Treatment of Heartburn in Non-Erosive Reflux Disease: A Randomized Trial; Digestive Disease Week® (DDW) 2024 abstract; May 18-21, Washington, D.C.
• Nicholas J. Shaheen, et. al.; Erosive Esophagitis Is Associated With High Health Care Resource Utilization And Frequent Changes In Medications; Digestive Disease Week® (DDW) 2024 abstract; May 18-21, Washington, D.C.
• Stuart J. Spechler, M.D., et. al.; Comparison of Local Investigator-Reported vs Centrally Adjudicated Los Angeles Grades of Erosive Esophagitis in Patients Screened for Participation in a Randomized Trial; Digestive Disease Week® (DDW) 2024 abstract; May 18-21, Washington, D.C.
• Dhyanesh Arvind Patel, et. al.; Real-World Treatment Patterns Among Newly Diagnosed Patients with Erosive Esophagitis in The U.S.; Digestive Disease Week® (DDW) 2024 abstract; May 18-21, Washington, D.C.
• Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet Needs in the Treatment of Gastroesophageal Reflux Disease . J Neurogastroenterol Motil. 2015 Jul 30;21(3):309-19. doi: 10.5056/jnm15105. 
• Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: A comprehensive review. Dis Esophagus . 2017;30(2):1-9.  
• Machicado J.D., Greer J.B., Yadav D. (2020) Epidemiology of Gastrointestinal Diseases. In: Pitchumoni C., Dharmarajan T. (eds) Geriatric Gastroenterology . Springer, Cham. https://doi.org/10.1007/978-3-319-90761-1_7-1.  
• U.S. Census Bureau. U.S. and World Population Clock. Accessed May 2022. https://www.census.gov/popclock . 

© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

4/24        US-VPZ-24-0154

Phathom Pharmaceuticals News MORE

Related stocks.

Take the Quiz: Find the Best State for You »

What's the best state for you ».

TV Upfront Presentations Clouded by Digital Video Ad Supremacy

FILE PHOTO: A view of the Walt Disney Studios in Burbank, California,. U.S. November 8, 2023. REUTERS/Mario Anzuoni/File Photo

By Dawn Chmielewski and Sheila Dang

(Reuters) - As television executives prepare lavish stage presentations in New York this week to dazzle advertisers during the annual TV upfront sales season, a harsh economic reality looms offstage -- digital video advertising now eclipses spending on traditional television ads.

The shift in spending and competition from tech players like Amazon has taken a toll on media companies' financial results, raising the stakes for the annual showcase of TV content to attract spending commitments from advertisers.

“We’ve definitely seen that audience erosion in linear TV in certain pockets -- especially more so in entertainment,” said Nicole McCurnin, director of advertising insights at ad tracking firm Guideline. “But I do see, broad strokes, ad companies’ attention is just going more so towards those digital platforms.” 

Digital video refers to a broad category of TV alternatives that includes paid streaming services like Netflix, social video platforms such as TikTok, free ad-supported TV offerings like Pluto TV and cable replacement services including YouTube TV. It will account for an estimated $62.9 billion in U.S. ad spending in 2024, according to an April report from the Interactive Advertising Bureau and Guideline.

That represents 52% of the projected spending on video advertising this year, reflecting a change in viewing habits nearly two decades in the making. 

Walt Disney, Warner Bros Discovery, Fox and Comcast's NBCUniversal all reported declines in domestic television ad revenue in the most recent quarter, though NBCU's exclusive streaming of an NFL Wild Card game on its Peacock service helped fuel revenue, offsetting those declines.

Many of the streaming services launched to capitalize on changing consumer viewing behavior "are still bleeding cash while declines in the traditional television business accelerate," said Richard Greenfield, media analyst at LightShed Partners. "They simply pivoted too late."

The fragmenting of the video landscape is well understood -- and media companies like NBCUniversal have developed new advertising tools that let marketers' messages ride along with their content, wherever it appears. For example, a T-Mobile ad featuring U.S. TV show "Saturday Night Live's" Chloe Fineman could air during the live network TV broadcast of “SNL,” appear the next day on NBCU’s Peacock streaming service and show up on social platforms like X, TikTok and YouTube.

“Regardless of where that person is who's in your target …  you can go follow them, wherever they are,” NBCUniversal global advertising chairman Mark Marshall told Reuters. “The technology and capability just wasn't available until this year.”

Ahead of the upfront advertiser presentations, Disney and Warner Bros Discovery announced they would combine their Disney+, Hulu and Max streaming services this summer in a bundle of programming reminiscent of cable television. Such a combination might reduce subscriber cancellations and perhaps coax money-losing competitors to follow suit, analysts said.

“We view a re-bundling of traditional media content on streaming platforms as a key to making the space investable again,” wrote TD Cowen’s Doug Creutz.

Meanwhile, digital rivals Amazon and Netflix are hosting their own advertiser presentations in New York -- the Seattle retail giant, for the first time -- to capture shifting ad dollars.

Amazon launched ads within Prime Video for all customers in January, requiring users to pay for a higher-priced tier to remove ads. The move will boost Amazon's revenue and likely come at the expense of traditional TV companies' revenue, said Brian Wieser, a longtime ad industry analyst, in a March report. 

Media companies are also tying up with tech giants to sell more ads. During a presentation to advertisers last month, Google announced that brands would be able to buy ad space with media companies like Paramount and Warner Bros Discovery through Google's automated tech tools, rather than working with salespeople. 

"I think we're going to hear more about programmatic ... particularly as consumption shifts to the digital and streaming ecosystem,” said Samantha Rose, strategic investment lead at Horizon Media, referring to the upfront presentations. 

(Reporting by Dawn Chmielewski in Los Angeles, Sheila Dang in Austin; Edited by Kenneth Li in New York)

Copyright 2024 Thomson Reuters .

Join the Conversation

Tags: United States

America 2024

Health News Bulletin

Stay informed on the latest news on health and COVID-19 from the editors at U.S. News & World Report.

Sign in to manage your newsletters »

Sign up to receive the latest updates from U.S News & World Report and our trusted partners and sponsors. By clicking submit, you are agreeing to our Terms and Conditions & Privacy Policy .

You May Also Like

The 10 worst presidents.

U.S. News Staff Feb. 23, 2024

Cartoons on President Donald Trump

Feb. 1, 2017, at 1:24 p.m.

Photos: Obama Behind the Scenes

April 8, 2022

Photos: Who Supports Joe Biden?

March 11, 2020

Who Is Prime Minister Robert Fico?

Laura Mannweiler May 15, 2024

Biden and Trump Agree to Debate

Lauren Camera May 15, 2024

Biden Muddies Message on Israel

Aneeta Mathur-Ashton May 15, 2024

Consumers Get a Break From Inflation

Tim Smart May 15, 2024

Trump Team Gets Its Shot at Cohen

Lauren Camera May 14, 2024

New China Tariffs: What to Know

Cecelia Smith-Schoenwalder May 14, 2024

research paper

Download 10000 free Research paper Icons in All design styles.

• User documentation